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Abstract 
 
Background: Due to worldwide spread of influenza A (H1N1) virus, the World Health Organization declared the 
first pandemic of influenza in four decades. This study aims to report the mortality from pandemic influenza A 
(H1N1) in Iran population and its epidemiologic and clinical characteristics up to December 21, 2009.  
 
Methods: The data were obtained from all provinces and reported to center for disease control of Ministry of 
Health and Medical Education (MOHME) of Iran through nationwide surveillance system for influenza A (H1N1) 
was implemented by MOHME since April 2009. 
 
Results: Of 3672 confirmed cases of influenza A (H1N1) in Iran between 22 May and 21 December 2009, 140 
(3.8%) deaths were reported, mostly in 15-65 year old (yo) age group (67%). The highest admission mortality 
rate was in > 65 yo group (107 deaths/1000 hospitalized cases). Of decedent patients, 54% had no long term 
condition or risk factor, 34% had one, 11% had two, and 1% had three. Diabetes mellitus, pregnancy, chronic 
respiratory diseases and hypertension were the most common underlying conditions. The most common clinical 
pictures of death were acute respiratory distress syndrome and viral pneumonia. Although 66% of decedent 
patients received oseltamivir, enough information was not available about time of onset of antiviral therapy. 
 
Conclusion: As death due to influenza A (H1N1) occurs in all age groups and in those with and without any 
predisposing factors, we recommend health policy makers to provide influenza vaccination for people with under-
lying conditions and respiratory hygiene for all people. 
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Introduction 
 
Due to worldwide spread of influenza A (H1N1) vi-
rus, on June 11, 2009, the World Health Organization 
(WHO) formally declared the first pandemic of influ-
enza in four decades.
1 Compared to seasonal flue, 
infection with influenza A (H1N1) usually results in a 
milder illness; however, a clinical spectrum compara-
ble to seasonal influenza has been described.
2-4 Fur-
thermore, the age groups affected by influenza A 
(H1N1) were reportedly younger.
5,6 Similar to the 
seasonal influenza, risk of fatality was reported to be 
higher in adults with 65 years of age or more, and 
those with certain chronic medical conditions.
5,7 Up 
to early June 2010, more than 18000 deaths attributa-
ble to influenza A (H1N1) have been reported 
worldwide.
4 So far, several studies have described 
mortalities associated with influenza A (H1N1) virus 
and its risk factors worldwide with various degrees of 
comprehensiveness. The aim of this study was to de-
scribe the data related to deaths due to influenza A 
(H1N1) infection including demographic characteris-
tics of decedent patients, risk factors for death and 
use of antiviral treatment by these patients in Iran by 
December 2009.  
 
 
Materials and Methods  
 
The data about decedent patients with influenza A 
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(H1N1) in this article were obtained through a nation-
wide surveillance system for influenza A (H1N1) im-
plemented by Ministry of Health and Medical Educa-
tion (MOHME) of Iran since April 2009. This surveil-
lance system was established in all provinces of Iran 
shortly after the announcement of first human cases of 
influenza A (H1N1) by WHO. It was based on multi-
ple expert panels at the onset of the pandemic in Iran 
and also the ongoing experience with surveillance of 
avian flu (started since September 2005). The methods 
of sampling and data gathering by this surveillance 
system were previously described by Gooya et al.
8  
A confirmed case of influenza A (H1N1) was de-
fined as a patient with high grade fever (>38°C) or at 
least two of following respiratory symptoms: cough 
sore throat, nasal obstruction/rhinorrhea, and fe-
ver/feverishness; the patient should also have H1N1 
viral infection confirmed by reverse transcriptase 
PCR (RT-PCR).  
Influenza A (H1N1)-related death was defined as 
any patient with a confirmed influenza A (H1N1) in-
fection in an ante mortem or post mortem specimen, 
who died from a clinically compatible illness or com-
plications attributable to that infection, with no com-
plete recovery between the onset of illness and de-
mise and also no alternative cause of death. 
 
 
Results 
 
Out of 3672 confirmed cases of influenza A (H1N1) 
in Iran between 22
nd May and 21
st December 2009, 
140 (3.8%) deaths (69 males and 71 females) were 
reported. The time distribution of these deaths was 
shown in Figure 1; most deaths occurred in October 
and November while no mortality was reported in 
May, June, July and December.  
Decedent patients ranged in age from 0 to 95 years 
(median age=27.5 years). Decedent patients were di-
vided into four age groups according to age classifi-
cation of WHO. The number of deaths, case fatality 
rates and also admission mortality rates in these age 
groups were demonstrated in Table 1. 
Of decedent patients, 75 (54%) had no long term 
underlying condition or risk factor, 47 (34%) had one, 
15 (11%) had two, and 2 (1%) had three. There was 
not enough information about one patient. The fre-
quency of long term conditions and risk factors in 
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Fig. 1: Monthly incidence of deaths among confirmed cases of pandemic A/H1N1 from May 22 to December 21, 
2009 in Iran. 
 
 
Table 1: Age specific number of deaths and admission mortality rates among reported confirmed cases of Pan-
demic 2009 Influenza A (H1N1) - Iran, May 22 through December 21.
Age group (years)  Number of deaths (%) Admission mortality rate 
(deaths per 1000 hospitalized cases) 
<5 17  (12)  64 
5-15 18  (13)  43 
15-65 94  (67)  48 
>65 11  (8)  107 Gouya et al. 
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decedent patients were demonstrated in Table 2. Dia-
betes mellitus, pregnancy, chronic respiratory diseas-
es and hypertension were the most common risk fac-
tors in decedent patients. 
 
Table 2: History of long term conditions and other risk 
factors among the patients dying from pandemic 
A/H1N1. Numbers in parentheses indicate number of 
patients with single long term condition or risk factor.
Risk factor No.  (%)
Respiratory:  
Asthma 4  (3) 
COPD 8  (6) 
Pulmonary Tuberculosis  1 (1) 
Cardiac:  
Hypertension 9  (1) 
Ischemic Cardiovascular Disease  1 (0) 
Heart Failure  5 (1) 
Other 1  (1) 
Endocrine:  
Diabetes mellitus  13 (2) 
Hematological:  
Fanconi anemia  1 (1) 
Β-thalassemia major  2 (1) 
Malignancy 5  (5) 
Other 1  (1) 
Neurological:  
Cerebral palsy  3 (3) 
Down syndrome  5 (4) 
Epilepsy 2  (2) 
Stroke 1  (0) 
Renal:  
Chronic kidney disease  5 (2) 
Gastrointestinal:  
Celiac Disease  1 (1) 
Rheumatologic Disease   1 (1) 
Pregnancy 11  (10) 
Drugs:  
Chronic corticosteroid consumption  2 (0) 
Addiction   1 (1) 
 
Clinical pictures of death in decedent patients 
were shown in Table 3; the most common picture was 
acute respiratory distress syndrome (ARDS) followed 
by viral pneumonia. Clinical picture of death was not 
reported in one patient. 
Among decedent patients, 93 (66%) received osel-
tamivir; however, no information was available about 
the time between the onset of symptoms and initiation 
of oseltamivir therapy. Eleven (8%) patients initially 
presented to health care facilities with cardiopulmonary 
arrest. Eight decedent patients (6%) received no antivi-
ral treatment. There was not sufficient information about 
the status of antiviral therapy in 28 (20%) patients. 
Table 3: Clinical pictures of death among the pa-
tients dying from pandemic A/H1N1. Numbers in 
parentheses indicate number of patients with single 
clinical picture of death.
Disease No. (%)
Respiratory  
Acute respiratory death syndrome 
(ARDS) 
81 (77) 
Viral pneumonia  29 (27) 
Secondary bacterial pneumonia  3 (3) 
Cardiovascular  
Myocarditis 7 (6)
Myocardial infarction  1 (1) 
Cardiac Arrest  1 (1) 
Pulmonary emboli 1 (1)
Neurologic  
Meningoencephalitis 12  (11) 
Sinus vein thrombosis 1 (0)
Status epilepticus  1 (0) 
Renal  
Acute Tubular Necrosis 2 (0)
Homeostatic    
Internal hemorrhage due to bleeding 
tendency 
4 (3) 
DIC 1  (1) 
 
 
Discussion 
 
Between 22
nd May to 21
st December 2009, 140 con-
firmed deaths due to influenza A (H1N1) were re-
ported in Iran. Most deaths occurred in October and 
November with no mortality was reported in May, 
June, July and December. A large proportion of dece-
dent patients had no predisposing risk factor or under-
lying condition. This is in contrast with reports from 
other countries where majority of patients had predis-
posing risk factors and underlying conditions.
5,7,9,10 
However, underlying conditions like diabetes melli-
tus, hypertension, chronic respiratory diseases like 
asthma and COPD, and pregnancy which were com-
mon predisposing factors in Iranian population, were 
also reported to be common underlying conditions in 
decedent patients in other reports.
5,7,9,10     
While most deaths occurred in those aging 5 to 65 
years, the highest admission mortality rates were ob-
served in those aging more than 65 years.  In a cross-
sectional study by Moghadami et al.,
11 it has been 
demonstrated that a large proportion of Iranian people 
were seropositive for polyclonal antibody against in-
fluenza A (H1N1); no difference was noted between 
those with and without history of flu-like illness in 
past six months. The authors proposed that this lack Mortality of pandemic influenza A 
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of difference could be explained by high rates of 
asymptomatic infection with influenza A (H1N1). 
Hence, it is very hard to estimate the exact number of 
Iranian patients infected with influenza A (H1N1) dur-
ing the period of study. Therefore, we preferred to use 
admission mortality rate instead of case fatality rate in 
this study. Similar to our findings which showed a J 
shaped age specific admission mortality rate, other 
studies have reported similar figures with highest case 
fatality rates in those aging more than 65 years.
5,7,12 
Although 66% of decedent patients received anti-
viral treatment, no information was available about its 
timing. Taking antiviral treatments, particularly in the 
first 48 hours of illness, has been reported to confer a 
survival benefit to the patients;
13 therefore, it is prob-
able that most of decedent patients in our study who 
used antiviral drugs did not receive this treatment in 
the first two days after onset illness. 
 
Conclusion 
 
Influenza A (H1N1) resulted in 140 confirmed deaths 
in Iranian population. Most deaths occurred in pa-
tients aging 5 to 65 years; however, the highest ad-
mission mortality rate was observed in those older 
than 65 years. Although majority of the decedent pa-
tients had no risk factor or underlying condition, dia-
betes mellitus, pregnancy, hypertensions and chronic 
respiratory diseases were among the most common 
reported conditions in decedent patients. 
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